Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Magnetar Financial LLC

Magnetar Financial LLC boosted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 125.8% in the fourth quarter, HoldingsChannel reports. The firm owned 27,511 shares of the biopharmaceutical company’s stock after buying an additional 15,328 shares during the period. Magnetar Financial LLC’s holdings in Theravance Biopharma were worth $259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its position in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 1,640 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock worth $2,766,000 after acquiring an additional 2,060 shares during the period. SG Americas Securities LLC raised its position in shares of Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,349 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Theravance Biopharma by 29.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 3,827 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Theravance Biopharma by 34.5% in the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 5,243 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $9.39 on Monday. The firm has a 50-day simple moving average of $9.32 and a two-hundred day simple moving average of $9.06. The company has a market cap of $464.53 million, a P/E ratio of -9.30 and a beta of 0.15. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Equities research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.